AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
December 01, 2022
December 01, 2022
WILMINGTON, Delaware, Dec. 1 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
CALQUENCE real-world evidence and long-term follow-up data, as well as research collaborations, will reinforce efficacy and safety across B-cell malignancies
Early clinical data will illustrate potential of multiple pipeline molecules, including TNB-486 (AZD0486), across hematologic malignancies
Research from Alexion, Astr . . .
* * *
CALQUENCE real-world evidence and long-term follow-up data, as well as research collaborations, will reinforce efficacy and safety across B-cell malignancies
Early clinical data will illustrate potential of multiple pipeline molecules, including TNB-486 (AZD0486), across hematologic malignancies
Research from Alexion, Astr . . .